Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: A prospective study in patients with ovarian cancer
Autore:
Mayerhofer, K; Bodner-Adler, B; Bodner, K; Saletu, B; Schindl, M; Kaider, A; Hefler, L; Leodolter, S; Kainz, C;
Indirizzi:
Univ Vienna, Sch Med, Dept Gynecol & Obstet, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 necol & Obstet, A-1090 Vienna, Austria Univ Vienna, Sch Med, Dept Psychiat, Div Sleep Res & Pharmacopsychiat, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 armacopsychiat, A-1090 Vienna, Austria Univ Vienna, Sch Med, Dept Med Comp Sci, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Med Comp Sci, A-1090 Vienna, Austria
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 5C, volume: 20, anno: 2000,
pagine: 4051 - 4055
SICI:
0250-7005(200009/10)20:5C<4051:APCDNC>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
FIRST-LINE CHEMOTHERAPY; OF-LIFE-QUESTIONNAIRE; PHASE-I; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC AGENT; STAGE-III; TAXOL; CARBOPLATIN; INFUSION; ENCEPHALOPATHY;
Keywords:
ovarian cancer; paclitaxel; neurotoxicity; encephalopathy; response;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Mayerhofer, K Univ Vienna, Sch Med, Dept Gynecol & Obstet, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ia
Citazione:
K. Mayerhofer et al., "A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: A prospective study in patients with ovarian cancer", ANTICANC R, 20(5C), 2000, pp. 4051-4055

Abstract

Background: The objective of this study was to evaluate the possible effects of a paclitaxel containing chemotherapy on different neuropsychological parameters in women with ovarian cancer. Materials and Methods: Twenty-eight women with histologically documented epithelial ovarian carcinoma and treated with a combination chemotherapy consisting of paclitaxel and carboplatin entered the study. The patients were tested with a battery of different neuropsychological tests before, after 3 cycles and at the end of the chemotherapy. Results: Twenty of the 28 patients responded to the chemotherapy (71%). Eleven patients (39%) developed peripheral neurotoxicity. The median values of 6 tests performed before the first chemotherapy cycle scored out of the normal range. These patients with deviant test results at the beginning of the paclitaxel/carboplatin. infusions did not deteriorate during chemotherapy. We found a statistically significant improvement of the alphabetical cross out test from the first to the third measurement (mean increase=4.07; 95% confidence interval =[0.99; 7.15]) (p<0.05), indicating an improvement of the short-term attention, the concentration and the constancy of working during chemotherapy. The other tests failed to show statistically significant changes during chemotherapy (p>0.05). Conclusion: According to our results, a chemotherapy consisting of paclitaxel/carboplatin caused no signs of acute central nervous toxicity or neuropsychological deterioration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 06:09:53